NCT06230198|Recruiting
The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery
TheRAPy
Loading search results
TheRAPy
Sponsor study identifier
interventional
4,500
1 country
4
Study Start
December 4, 2024
Actual (reported)Primary Completion
January 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 23, 2023
Actual (reported)January 30, 2024
Actual (reported)December 4, 2024
Actual (reported)January 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Feasibility of implementing a full-scale randomized cluster crossover trial
Feasibility is defined as adherence \>90% to both institutional policies applied in random sequence.
6 months
Data Collection about Critical Parameters
6 months
sites implement retrograde autologous priming (RAP) during cardiac surgery
sites implement crystalloid priming use during cardiac surgery
sites follow an institutional policy of routine use of retrograde autologous priming (RAP) during cardiac surgery
sites implement crystalloid priming use during cardiac surgery
St. Boniface Hospital
Winnipeg, Manitoba, R2H 2A6, Canada
Hamilton General Hospital
Hamilton, Ontario, L8S 48L, Canada
Jessica Spence, MD, PhD
Population Health Research Institute
Jessica Spence
CONTACT
First Submitted
December 23, 2023
First Posted
January 30, 2024
Study Start
December 4, 2024
Actual (reported)Primary Completion
January 2026
Trial of Indication-Based Transfusion of Red Blood Cells in ECMO
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Montreal Heart Institute
Montreal, Quebec, H1T 1C8, Canada
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, H2X 0A9, Canada
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
March 4, 2025
Record last verified: 2025-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: